Fosciclopirox

Fosciclopirox (CPX-POM) suppresses growth of urothelial cancer by targeting the γ-secretase complex. Fosciclopirox selectively delivers the active metabolite, Ciclopirox (CPX), to the entire urinary tract. Ciclopirox has anticancer activity in a number of solid and hematologic malignancies[1][2].

Product Specifications

CAS Number

[1380539-06-9]

Product Name Alternative

CPX-POM

UNSPSC

12352005

Hazard Statement

H302, H314

Target

γ-secretase

Type

Reference compound

Related Pathways

Neuronal Signaling; Stem Cell/Wnt

Applications

Neuroscience-Neurodegeneration

Field of Research

Cancer; Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/fosciclopirox.html

Purity

99.66

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C1C=C(C)C=C(C2CCCCC2)N1OCOP(O)(O)=O

Molecular Formula

C13H20NO6P

Molecular Weight

317.27

Precautions

H302, H314

References & Citations

[1]Weir SJ, et al. Fosciclopirox suppresses growth of high-grade urothelial cancer by targeting the γ-secretase complex. Cell Death Dis. 2021 May 31;12 (6) :562.|[2]Weir SJ, Wood R, Schorno K, Brinker AE, Ramamoorthy P, Heppert K, Rajewski L, Tanol M, Ham T, McKenna MJ, McCulloch W, Dalton M, Reed GA, Jensen RA, Baltezor MJ, Anant S, Taylor JA 3rd. Preclinical Pharmacokinetics of Fosciclopirox, a Novel Treatment of Urothelial Cancers, in Rats and Dogs. J Pharmacol Exp Ther. 2019 Aug;370 (2) :148-159.